-
Metabolon Expands Microbiome Panel to Strengthen Industry Leadership in Functional Microbiome Research
Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response MORRISVILLE, N.C., July 15, 2026 /PRNewswire/ — Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced an expansion of…
-
NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists’ Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act
WASHINGTON, July 14, 2026 /PRNewswire/ — On July 14, 2026, the U.S. Fish and Wildlife Service (“USFWS”) for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals (“PETA”) and other activist groups to list long-tailed macaque (“LTM”) monkeys (Macaca fascicularis) under the U.S. Endangered Species Act (“ESA”). The…
-
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners July 12, 2026 11:18 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data…
-
Medicine Beyond Borders: Zydus Hospital, Ahmedabad, Emerges as a Preferred Destination for International Patients
AHMEDABAD, India, July 7, 2026 /PRNewswire/ — Quality healthcare should never be a matter of geography or means, yet for patients in many parts of the world, it still is. As illnesses grow more complex and treatments advance, the gap between what is medically possible and what is locally accessible keeps widening for many. Patients travelling…
-
World’s First International Patient Begins Treatment with Newly Approved Solid Tumor CAR-T Therapy at Jiahui International Cancer Center
SHANGHAI, July 6, 2026 /PRNewswire/ — Jiahui International Cancer Center (JICC) has welcomed the world’s first international patient to begin treatment with Satri-cel, the world’s first approved CAR-T therapy for a solid tumor, marking a historic milestone in expanding global access to China’s latest oncology innovations. Josh, a 59-year-old patient from New Zealand with advanced…
-
STARMED Receives FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication
SEOUL, South Korea, July 1, 2026 /PRNewswire/ — STARMED, a medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication (510(k) number: K252833). The clearance took effect on 26 May 2026. The company’s system may now…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa Hopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approval More than…
-
Desert Hope Treatment Center Launches First Responder Lifeline Program, Offering Confidential Care for Frontline Heroes
LAS VEGAS, June 18, 2026 (GLOBE NEWSWIRE) — Desert Hope Treatment Center, a leading addiction treatment center in Las Vegas, has introduced its First Responder Lifeline Program, designed specifically for law enforcement officers, firefighters, EMTs, dispatchers, corrections officers, and other public safety professionals. The program was developed in collaboration with public safety leaders, including representatives…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App
Ahmedabad, Gujarat, India India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to one of the world’s largest medicine markets, millions of Indian families continue to struggle with the high cost of treatment. Studies show that over 50% of healthcare expenses in India are still paid out-of-pocket, leaving many to either delay care…
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 June 07, 2026 19:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine…
-
Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews
Editorial note: This article is an independent informational evaluation of publicly available product information. It is not medical advice, not a diagnosis or treatment recommendation, and not an endorsement of any brand. Dietary supplements are not medical devices and are not intended to diagnose, treat, cure, or prevent any disease, including menopause. Statements have not…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.